Bovine leukemia virus (BLV) is a B-lymphotropic oncogenic retrovirus whose transcriptional promoter is located in the viral 5 0 long terminal repeat (LTR). To date, no B-lymphocyte-specific cis-regulatory element has been identified in this region. Since ETS proteins are known to regulate transcription of numerous retroviruses, we searched for the presence in the BLV promoter region of binding sites for PU.1/Spi-1, a B-cell-and macrophage-specific ETS family member. In this report, nucleotide sequence analysis of the viral LTR identified a PUbox located at À95/À84 bp. We demonstrated by gel shift and supershift assays that PU.1 and the related Ets transcription factor Spi-B interacted specifically with this PUbox. A 2-bp mutation (GGAA-CCAA) within this motif abrogated PU.1/Spi-B binding. This mutation caused a marked decrease in LTR-driven basal gene expression in transient transfection assays of B-lymphoid cell lines, but did not impair the responsiveness of the BLV promoter to the virus-encoded transactivator Tax BLV . Moreover, ectopically expressed PU.1 and Spi-B proteins transactivated the BLV promoter in a PUbox-dependent manner. Taken together, our results provide the first demonstration of regulation of the BLV promoter by two B-cell-specific Ets transcription factors, PU.1 and Spi-B. The PU.1/Spi-B binding site identified here could play an important role in BLV replication and B-lymphoid tropism.
Introduction
Bovine leukemia virus (BLV) is an oncogenic retrovirus, which belongs to the Deltaretrovirus genus and is structurally and biologically closely related to the human T-lymphotropic viruses HTLV-I and HTLV-II (Rosen et al., 1985 (Rosen et al., , 1986 Sagata et al., 1985) . BLV has a B-lymphotropic tropism and is the etiologic agent of enzootic bovine leukosis (EBL), a chronic lymphoproliferative disease often associated with persistent lymphocytosis (PL) and/or neoplastic proliferation of B lymphocytes (Burny et al., 1987a (Burny et al., , b, 1994 Kettmann et al., 1994; Willems et al., 1999 Willems et al., , 2000 . In cattle, the majority of the infected animals remain clinically asymptomatic during their entire life. Only up to onethird of BLV-infected cattle develop PL, and less than 5% will die consecutively to lymphomas and/or lymphosarcoma (Ferrer, 1979) . Investigations in different animal models have revealed that sheep is the ideal host to study BLV-induced leukemia. Indeed, sheep that are experimentally inoculated with BLV are readily infected, and some develop B-cell tumors at higher frequencies and after a shorter latency period than naturally inoculated cattle (Djilali et al., 1987; Aida et al., 1989) . BLV infection is characterized by a long latency period associated with a lack of viral expression (Lagarias and Radke, 1989) . This latency is likely to be a viral strategy to escape the host immune response.
The BLV transcriptional promoter is located in the proviral 5 0 long terminal repeat (LTR), which is composed of the U3, R, and U5 regions. The U3 region contains several cis-acting elements important for promoter activity: a CAAT box, a TATA box (Derse and Casey, 1986; Katoh et al., 1989) , a glucocorticoidresponsive element (Bloom et al., 1979 (Bloom et al., , 1980 Niermann and Buehring, 1997; Xiao and Buehring, 1998) , a NF-kB-like motif (Brooks et al., 1995 (Brooks et al., , 1998 , and three 21-bp enhancers that include an imperfectly conserved cyclic-AMP-responsive element (CRE). At least three proteins, CRE-binding protein (CREB) and activating transcription factor-1 and -2 (ATF-1 and ATF-2) bind to these 21-bp enhancers (Adam et al., , 1996 , which are also called Tax-responsive elements (TxREs) because transactivation of the BLV LTR by the virusencoded transcriptional activator Tax BLV requires these sequences (Derse, 1987; Katoh et al., 1989) . In addition to these cis-acting elements all situated in U3, viral expression is also regulated by sequences downstream of the transcription initiation site (nt +1 at the U3/R junction) including an upstream stimulatory factor (USF) binding site in R (Calomme et al., 2002) and an interferon regulatory factor (IRF) binding site in U5 (Kiermer et al., 1998) .
Members of the ETS family of transcription factors are involved in several developmental and physiological processes, and, when deregulated in their expression or mutated, can contribute to a variety of cancers. ETS transcription factors are also known to regulate transcription of several retroviruses including HTLV-I (Bosselut et al., 1990; Gitlin et al., 1991; Clark et al., 1993) , human immunodeficiency virus type 1 (HIV-1) (Holzmeister et al., 1993; Van Lint et al., 1994; Lodie et al., 1998; Verhoef et al., 1999; Jeeninga et al., 2000; Posada et al., 2000) and type 2 (HIV-2) (Leiden et al., 1992; Markovitz et al., 1992; Myers et al., 1995) , mouse mammary tumor virus (MMTV) (Aurrekoetxea-Hernandez and Buetti, 2000) , and equine infectious anemia virus (EIAV) Carvalho and Derse, 1993) .
Owing to the B-lymphoid tropism of BLV, we analysed the nucleotide sequence of the BLV promoter region for the presence of binding sites for PU.1/Spi-1, an ETS family member (Moreau-Gachelin, 1994 ) that is highly expressed in B lymphocytes and myeloid cells (Hromas et al., 1993; Klemsz et al., 1990) , and which has been previously cloned by different methodologies (Moreau-Gachelin et al., 1988 Goebl, 1990; Klemsz et al., 1990; Paul et al., 1991) . This analysis revealed the presence of two potential PU.1 binding sites in the BLV U3 region, located between the middle and the proximal TxREs : 5 0 -AAAGGGGAAGTT-3 0 (nt À95/À84) and 5 0 -TTTCGGGAAAGG-3 0 (nt À88/À77), respectively. PU.1, also known as Spi-1, is the most divergent member of the ETS family bearing only 30% homology to most other ETS family members within the common ETS DNA-binding domain. A purine-rich motif (GGAA) is typically the minimal core sequence common to PU.1-responsive elements (Moreau-Gachelin, 1994) , also called PU boxes. The critical role of PU.1 in B cell and myeloid lineages development primarily results from the presence of PU.1 binding sites in enhancer and promoter regions of several genes that are expressed during differentiation along these lineages.
The objective of the present study was to characterize physically and functionally the two potential PU.1 sites located in the BLV U3 region. Using a combination of in vitro binding studies and ex vivo transient expression assays in B-lymphoid cell lines, we demonstrate that the B-cell-specific transcription factor PU.1 and also the highly related Ets transcription factor Spi-B are major activators of the BLV promoter.
Results
Transcription factors PU.1 and Spi-B specifically interact with the U3 region of the BLV 5 0 LTR
A database search for potential transcription factor binding sites in the BLV 5 0 LTR revealed the presence of two potential PU.1 binding sites (nt À95/À84 and nt À88/À77 according to the sequence reported by Willems et al., 1993) , which may be relevant to the B-lymphoid tropism of the virus. Interestingly, these two putative PU boxes are located in a region in which NF-kB-like motifs were previously identified (Brooks et al., 1995) . The binding of NF-kB transcription factors could therefore interfere with the occupancy of the PU.1 sites. For this reason, we designed a double-stranded oligonucleotide encompassing both the NF-kB region and the potential PU.1 sites. This 49-bp oligonucleotide (referred to as À118/À70) was used as probe in electrophoretic mobility shift assays (EMSAs). Since PU.1 is predominantly expressed in macrophages and B cells, we first investigated the tissue distribution of nuclear factors binding to the À118/À70 probe. This probe was incubated with nuclear extracts from different origins: peripheral blood mononuclear cells (PBMCs) derived from a BLVinfected sheep (BLV-infected sheep M298 presenting a persistently elevated lymphocyte count and an inverted B/T-lymphocyte ratio) ( Figure 1b Figure 1b , lanes 8 and 9). A major retarded protein-DNA complex (C1) was detected and presented a monocyte/macrophage-and B-cell-specificity. This cell-type-specific DNA-binding activity parallels PU.1 gene expression.
To assess the sequence specificity of the C1 complex, unlabeled double-stranded oligonucleotides were used as competitors in EMSAs with nuclear extracts from BLV-infected ovine PBMCs (Figure 1c) . Binding of proteins in the major complex (C1) was shown to be sequence specific, since the formation of this complex was competed by a molar excess of the unlabeled homologous À118/À70 oligonucleotide ( Figure 1c , lanes 2-5), but not by the same molar excess of two heterologous oligonucleotides of unrelated sequence ( Figure 1c , lanes 6-9 and 10-13, respectively). Moreover, the C1 complex was specific for the PU.1 site since an unlabeled oligonucleotide (SV40 PU.1) containing the well-characterized PU box from the enhancer of a Simian Virus 40 (SV40) variant inhibited specifically the formation of C1 (Figure 2a , lanes 5-7), whereas a mutated version of this oligonucleotide (SV40 PU.1mut), in which the two guanines of the GGAA core were changed to cytosines, failed to compete (Figure 2a, lanes 8-10) . Similar results were observed with Raji nuclear extracts (data not shown).
To provide further evidence that the transcription factor PU.1 can directly bind the À118/À70 region, we compared the electrophoretic mobility of complex C1 (Figure 2b , lane 1) with that of the complex formed by purified PU.1 protein produced in Spodoptera frugiperda cells (SF9 cells) infected by an Ac-NVP-PU.1 recombinant baculovirus. A retarded band PU.1 and Spi-B regulate the BLV promoter A Dekoninck et al was observed which presented an electrophoretic mobility identical to that of complex C1 observed with the PBMCs extracts ( Figure 2b , lane 4). This latter complex was specific since it was inhibited by an excess of unlabeled À118/À70 homologous oligonucleotide or by the SV40 PU.1 oligonucleotide, but not by the SV40 PU.1mut oligonucleotide (data not shown). Control baculovirus did not generate any shift (Figure 2b , lane 5).
To determine directly that the specific major complex C1 contained PU.1, supershift assays were performed. Preimmune serum or antiserum specific for PU.1 was incubated with nuclear extracts prepared from BLV-infected ovine PBMCs prior to the addition of the À118/À70 probe (Figure 2b ). The anti-PU.1 antibody interfered with the formation of complex C1 and yielded a supershifted complex, designated supershifted complex S1 (Figure 2b, lane 3, arrow) . In contrast, the preimmune serum did not affect complex C1 formation ( Figure 2b , lane 2), indicating the specificity of the protein-antibody interactions. Similar results were observed with Raji nuclear extracts (data not shown).
In additional supershift assays, we added increasing amounts of the anti-PU.1 antibody to the binding reaction in order to titrate complex C1. However, the retarded complex C1 was not entirely supershifted even with large amounts of anti-PU.1 antiserum (data not shown). This was an indication that complex C1 might contain additional protein(s) able to interact with the À118/À70 probe and exhibiting the same electrophoretic mobility as PU.1 in EMSA. Since Spi-B, a highly PU.1-related protein, shares the same DNAbinding specificity as PU.1 (Ray et al., 1992; Chen et al., 1995b; Ray-Gallet et al., 1995) , we suspected that Spi-B could also bind to the À118/À70 probe. To test this hypothesis, we performed supershift experiments with an antibody specific for Spi-B. Addition of such an antibody did result in a partial supershift of complex C1 (B30% of the C1 complex was supershifted) (Figure 2c, lane 5, arrow) . This supershift, designated supershifted complex S2, barely migrated out of the well. Importantly, addition of antisera to both PU.1 and Spi-B resulted in a complete disappearence of complex C1 (Figure 2c , lanes 6 and 7), demonstrating that the C1 complex consisted of both PU.1 and Spi-B in different ratios.
Taken together, these results demonstrate that both PU.1 and Spi-B specifically interact with the À118/À70 sequence of the BLV 5 0 LTR U3 region.
The À118/À70 probe does not bind NF-kB transcription factors
In addition to the major C1 complex, five other retarded protein-DNA complexes were also observed with the À118/À70 probe ( Figure 1c ): a slow-migrating complex, designated C2, which will be discussed later; a fainter band observed above C2 (asterisk) and three fastermigrating complexes observed with all nuclear extracts tested. To evaluate the sequence specificity of these five 0 -GGAA-3 0 of each site is indicated by a thicker bar. The asterisks indicate the mismatches in the À88/À77 potential PU.1 site with respect to the PU.1 consensus sequence derived by Galson et al. (1993) . (b) The À118/À70 oligonucleotide was used as a probe and incubated with 5 mg of nuclear extracts from BLV-infected ovine PBMCs (lane 1), the B-lymphoid cell lines Raji and Daudi (lanes 2 and 3), the myeloid cell lines RAW and U937 (lanes 4 and 5), the epithelial cell line HeLa (lane 6), the fibroblastic cell line NIH3T3 (lane 7), and the T-lymphoid cell lines Jurkat and Sup T1 (lanes 8 and 9). The major retarded DNA-protein complex (C1), observed with BLV-infected ovine PBMCs, and with B-lymphoid and myeloid nuclear extracts, is indicated by an arrow. The free probe (FP) is also indicated. (c) The À118/À70 oligonucleotide probe was incubated with 4 mg of nuclear extracts from BLV-infected ovine PBMCs in the absence of competitor (lane 1) or in the presence of increasing concentrations (fivefold, 10-, 30-, and 150-fold molar excesses) of the homologous À118/À70 oligonucleotide (lanes 2-5), of the heterologous IRF-1 oligonucleotide (lanes 6-9), or of the heterologous HIV-1 E-box oligonucleotide (lanes 10-13). The IRF-1 oligonucleotide is a consensus binding site for IRF-1 (obtained from Santa Cruz Biochemicals, Santa Cruz, CA, USA), whose sequence of the coding strand is 5 0 -GGAAGCGAAAAT-GAAATTGACT-3 0 . The sequence of the coding strand of the HIV-1 E-box oligonucleotide is 5 0 -ATTTCATCACGTGGCCC-GAG-3 0 (nt +281-+300 according to the numbering of the HIV-1 BRU genome, where nt +1 is the start of U3 in the 5 0 LTR). The major DNA-protein complex C1 and the hypothetical NF-kB complex C2 are indicated by arrows. The nonspecific complex is indicated by an asterisk PU.1 and Spi-B regulate the BLV promoter A Dekoninck et al other retarded complexes, unlabeled double-stranded oligonucleotides were prepared and used as competitors in EMSAs with nuclear extracts from BLV-infected ovine PBMCs ( Figure 1c ). Binding of four of the five complexes (i.e. all except the complex labeled with an asterisk) was shown to be sequence specific by competition EMSAs ( Figure 1c) . Indeed, the formation of these four complexes was competed by a molar excess of the unlabeled homologous À118/À70 oligonucleotide ( Figure 1c , lanes 2-5), but not by the same molar excess 0 -end-labeled and used as a probe. This probe was incubated with 5 mg of nuclear extracts from BLV-infected ovine PBMCs in the absence of competitor (lane 1) or in the presence of increasing concentrations (fivefold, 10-, 20-fold molar excesses) of the homologous À118/À70 oligonucleotide (lanes 2-4), of the SV40 PU box oligonucleotide (SV40 PU.1) (lanes 5-7), or of a mutated version of this oligonucleotide (SV40 PU.1mut), in which two guanines crucial for PU.1 binding were changed to cytosines (lanes 8-10). The major DNA-protein complex C1 is indicated by an arrow. The sequences of the coding strand of the SV40 PU.1 oligonucleotide and of its mutated version (the SV40 PU.1mut oligonucleotide) are 5 0 -TGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTA-3 0 and 5 0 -TGAAATAACCTCTGAAAGACCAACTTGGTTAGGTA-3 0 , respectively. The FP is indicated. (b) A PU.1-specific antiserum (lane 3) or the preimmune rabbit serum as a negative control (lane 2) was incubated with 3 mg of nuclear extracts from BLV-infected ovine PBMCs prior to the addition of the À118/À70 probe. This probe was also incubated with whole-cell extracts from SF9 cells infected with an Ac-NVP-PU.1 recombinant baculovirus (PU.1 baculovirus, lane 4) or from uninfected SF9 cells (baculovirus control, lane 5). The major DNA-protein complex C1, the supershifted complex S1, and the FP are indicated by arrows. (c) Antisera specific for PU.1 (2 ml in lanes 3 and 7, and 1 ml in lane 6) or for Spi-B (2 ml in lanes 5 and 7, and 1 ml in lane 6), or preimmune sera (2 ml Pre-PU.1 in lane 2, and 2 ml Pre-Spi-B in lane 4) were incubated with 3 mg of nuclear extracts from BLV-infected ovine PBMCs prior to the addition of the À118/À70 probe. The major retarded DNA-protein complex C1, the supershifted complexes S1 and S2, and the FP are indicated by arrows PU.1 and Spi-B regulate the BLV promoter A Dekoninck et al of two heterologous oligonucleotides of unrelated sequence ( Figure 1c , lanes 6-9 and 10-13, respectively). In contrast, the faint band indicated by an asterisk was inhibited by all competitor oligonucleotides and was assumed to be nonspecific ( Figure 1c) .
As mentioned earlier, NF-kB-like binding sites had been previously reported in the À118/À70 region (Brooks et al., 1995) . This region has been shown by Brooks and colleagues to bind in EMSAs several purified bacterially expressed proteins of the NF-kB family: p52, p50, p65 (RelA). For this reason, we tested whether complex C2 (which could correspond to NF-kB binding based on profil migration) contained NF-kB proteins. For this, supershift experiments were performed using antibodies directed against individual members of the NF-kB family of transcription factors ( Figure 3a ). Antibodies directed against p65 (RelA), p50, p52, RelB and c-Rel were incubated with nuclear extracts prepared from Raji cells prior to the addition of the À118/À70 probe ( Figure 3a ). However, none of these antibodies interfered with formation of complex C2 ( Figure 3a , lanes 3-7) and the binding patterns were similar to those observed with the two control preimmune sera ( Figure 3a , lanes 1 and 2). Similar results were observed with nuclear extracts prepared from BLV-infected ovine PBMCs (data not shown). As specificity control, these anti-NF-kB antibodies were shown to efficiently supershift or block NF-kB complexes formed in EMSAs with the HIV-1 NF-kB probe (data not shown) or with other NF-kB probes (Bours et al., 1993; Lopez-Rovira et al., 2000) . Moreover, formation of complex C2 was not inhibited by an excess of an unlabeled kB consensus oligonucleotide (data not shown). We next examined the binding of NF-kB to the À118/À70 probe using purified recombinant fusion proteins: GST-p50 and GST-p65. Our data shown in Figure 3b demonstrated the binding of both GST-p50 and GST-p65 to the À118/À70 probe ( Figure 3b , lanes 2 and 3, respectively). We also showed supershifts of these complexes by antibodies directed against p50 and p65 (data not shown). Our results are thus in agreement with those reported by Brooks et al (1995) , since they have observed the binding of purified NF-kB proteins to the À118/À70 region, but could never demonstrate NF-kB binding to this region by using nuclear extracts and a BLV LTR probe.
In order to characterize the other specific complexes observed with the À118/À70 probe, additional supershift experiments were performed with antibodies directed either against proteins known to have a DNA-binding specificity similar to that of PU.1 and Spi-B (such as GABP, Nuchprayoon et al., 1997; Rosmarin et al., 1995b; Smith et al., 1998) . Indeed, in many cases, PU.1 has been shown to control gene transcription via interaction with other cis-bound regulatory factors (Pongubala et al., 1993; Eisenbeis et al., 1995) . However, the results of our supershift experiments showed that none of the tested antibodies interfered with formation of any of the four sequence-specific retarded complexes observed with the À118/À70 probe (data not shown). 
LTR BLV U3 region
In order to better characterize the DNA sequence requirements for the binding of PU.1/Spi-B to the À118/À70 region of the BLV LTR, we used as probes oligonucleotides containing GG to CC transversions in the core region of either the first (nt À95/À84), or the second (nt À88/À77), or both potential PU.1/ Spi-B binding sites. The DNA sequences of the noncoding strand of these double-stranded oligonucleotides (named À118/À70-mut1, À118/À70-mut2 and À118/À70-mut1+2, respectively) are shown in Figure 4a . Figure 4 Mutagenesis of the PU.1/Spi-B binding site located in the BLV U3 region. (a) Nucleotide sequence of the noncoding strand of the À118/À70 oligonucleotide. The underlined bases indicate the two GGAA core sequences. For the À118/À70-mut1, À118/À70-mut2, and À118/À70-mut1+2 oligonucleotides, only the bases that are changed compared with the wild-type À118/À70 sequence are indicated. (b) The À118/À70 and mutated oligonucleotides were 5 0 end labeled and used as probes in EMSAs. These probes were incubated either with nuclear extracts from BLV-infected ovine PBMCs or with three different dilutions (1:1000, 1:2000, 1:5000) of extracts from SF9 cells infected with an Ac-NVP-PU.1 recombinant baculovirus. The figure shows only the specific retarded bands of interest. The C1 and PU.1 complexes are indicated by arrows. (c) The À118/À70 wild-type and mutated oligonucleotides were tested in competition EMSAs. The À118/À70 oligonucleotide was used as probe and incubated with 5 mg of nuclear extracts from BLV-infected ovine PBMCs either in the absence of competitor (lane 1) or in the presence of increasing concentrations (fivefold, 10-, 25-, and 75-fold molar excesses) of the homologous À118/À70 oligonucleotide (lanes 2-5), of the À118/À70-mut1+2 oligonucleotide (lanes 6-9), of the À118/À70-mut1 oligonucleotide (lanes10-13), or of the À118/À70-mut2 oligonucleotide (lanes 14-17) . The major DNA-protein complex C1 is indicated by an arrow. The figure shows only the specific retarded band of interest PU.1 and Spi-B regulate the BLV promoter A Dekoninck et al
The wild-type and mutated versions of the À118/À70 probe were incubated either with nuclear extracts from BLV-infected ovine PBMCs or with different dilutions of recombinant PU.1 protein (Figure 4b) . A specific retarded complex was detected with both the wild-type À118/À70 and the À118/À70-mut2 probe (Figure 4b,  lanes 1 and 4) . In contrast, we did not detect any PU.1/ Spi-B binding with the À118/À70-mut1+2 and the À118/À70-mut1 oligonucleotide probes (Figure 4b,  lanes 2 and 3) , indicating that the nt À95/À84 site was solely responsible for the specific binding of PU.1/Spi-B to the À118/À70 region. Of note, the binding of PU.1 to the À118/À70 probe was slightly impaired by the mutation within the À88/À77 region (Figure 4b , lane 4), probably as a consequence of modifications in the sequences flanking the À95/À84 PU box. Similar results were observed with nuclear extracts prepared from Raji cells and from Daudi cells (data not shown). The effects of the selected mutations were confirmed by competition EMSAs using the À118/À70 oligonucleotide as a probe and nuclear extracts from BLV-infected ovine PBMCs (Figure 4c) or from Raji cells (data not shown). Specifically, formation of the PU box-specific retarded complex (C1) was inhibited in a dose-dependent manner by competition with an excess of either the unlabeled homologous oligonucleotide (Figure 4c, lanes 2-5) or the unlabeled À118/À70-mut2 oligonucleotide (Figure 4c, lanes 14-17) . In contrast, the À118/À70-mut1+2 and À118/À70-mut1 oligonucleotide competitors failed to compete for formation of complex C1 (Figure 4c , lanes 6-9 and lanes 10-13, respectively). Consistent with the data of Figure 4b , PU.1/Spi-B binding was more efficiently competed by the homologous oligonucleotide than by the À118/À70-mut2 oligonucleotide (Figure 4c , compare lanes 2-5 with lanes 14-17).
Taken together, our results identify a unique PU.1/ Spi-B binding site in the U3 region of the BLV 5 0 LTR (nt À95/À84). We also report a point mutation, referred to as À118/À70-mut1, that abrogates the binding of PU.1/Spi-B to this site.
The PU box in the U3 region of the BLV 5 0 LTR is required for optimal basal gene expression from the BLV promoter
In order to examine the functional role of the PU.1/Spi-B binding site in the basal (Tax BLV -independent) transcriptional activity of the BLV promoter, the same 2-bp mutation described above (À118/À70-mut1) was introduced by site-directed mutagenesis in the context of a pLTR BLV -luciferase reporter construct, called pLTRwt-luc and containing the firefly luciferase (luc) gene under the control of the complete 5 0 LTR (nt À211 to +320) of the 344 BLV provirus. Strain 344 is an infectious and pathogenic molecular clone. The mutated plasmid was designated pLTRmut1-luc. As controls, we also introduced the mutations À118/À70-mut2 and À118/À70-mut1+2 in the context of the pLTRwt-luc reporter construct to generate the mutated plasmids pLTRmut2-luc and pLTRmut1+2-luc, respectively. To assess the transcriptional regulatory function of the PU.1/Spi-B binding site (nt À95/À84), the constructs pLTRwt-luc, pLTRmut1-luc, pLTRmut2-luc and pLTRmut1+2-luc were transiently transfected into the human EBV-positive B-lymphoid cell lines Raji and Daudi. At 44 h post-transfection, cells were lysed and assayed for luciferase activity. Results presented in Figure 5a show that both the À118/À70-mut1 and the À118/À70-mut1+2 mutations reproducibly reduced the basal activity of the BLV promoter by approximately 30% in Raji cells. These two mutations caused a 55-60% decrease in basal LTR-driven gene expression in Daudi cells (Figure 5b) . These results are consistent with the binding of a transcriptional activator, such as PU.1 or Spi-B, to the À95/À84 PU box. Intriguingly, the À118/À70-mut2 mutation increased the basal activity of the BLV promoter by approximately 50% in both Raji and Daudi cells, presumably as a consequence of a cisregulatory element artificially created by the mutation À118/À70-mut2 within the U3 region.
To confirm these functional results in EBV-negative B-lymphoid cell lines, the same reporter contructs (pLTRwt-luc, pLTRmut1-luc, pLTRmut2-luc and pLTRmut1+2-luc) were transiently transfected into the human cell line DG75 and into the murine cell line A20. As shown in Figure 5c and d, the À118/À70-mut1 mutation caused a 45 and a 50% decrease in basal LTRdirected gene expression in DG75 and A20 cells, respectively. As observed in Raji and Daudi cells, the À118/À70-mut2 mutation caused an increase in BLV 5 0 LTR-driven gene expression in both the DG75 and A20 cell lines. The differential effects of the mutations between the different cell lines may result from differences in the expression, binding and/or transcriptional activity of PU.1 and Spi-B, of transcriptional cofactors and/or of other DNA-binding proteins.
Our functional results thus demonstrate a positive regulatory role of the À95/À84 PU box located in the U3 region of the BLV 5 0 LTR in Tax-independent BLV promoter-driven expression.
Ectopic expression of the PU.1 and Spi-B transcription factors upregulates BLV promoter activity through the À95/À84 PU box To ascertain that PU.1 and Spi-B are functional on the BLV promoter, transactivation experiments were performed in NIH3T3 cells that lack endogenous PU.1 and Spi-B proteins. Cells were cotransfected with either pLTRwt-luc, or pLTRmut1-luc, or pLTRmut2-luc, or pLTRmut1+2-luc together with increasing doses of a PU.1 expression plasmid (pJ6-PU.1). As shown in Figure 6a , PU.1 transactivated the wild-type and mut2 BLV promoter constructs in a dose-dependent manner up to 2.64-and 3.38-fold, respectively. In contrast, the pLTRmut1-luc and pLTRmut1+2-luc constructs failed to be activated by PU.1. Similar results were obtained when cotransfection studies were performed using HeLa and Cos-7 cells (data not shown). NIH3T3 cells were also cotransfected with either pLTRwt-luc or pLTRmut1-luc together with increasing doses of the PU.1 and Spi-B regulate the BLV promoter A Dekoninck et al Spi-B expression plasmid DEB-SpiB (Figure 6b ) or pcDNA-3-Spi-B (data not shown). As shown in Figure 6b , Spi-B transactivated the wild-type promoter in a dose-dependent manner up to 3.02-fold, whereas the pLTRmut1-luc reporter plasmid failed to be activated by Spi-B. Moreover, ectopic expression of both PU.1 and Spi-B together did not reveal any cooperative effect between the two proteins in additional transfection Mutation of the À95/À84 PU box does not affect activation of the BLV 5 0 LTR by Tax BLV Efficient transcription and replication of the BLV genome require both the viral LTR and the virusencoded transcriptional activator Tax BLV , which functions through the TxREs in U3. Considering that the À95/À84 PU box is located between the middle (À123) and the proximal (À48) TxREs, we next studied the effect of mutating the À95/À84 PU box on the response of the BLV promoter to Tax BLV . Toward this end, Raji cells were cotransfected with either pLTRwt-luc or pLTRmut1-luc and increasing amounts of a Tax BLV expression vector, pSG-TAX BLV . At 44 h post-transfection, luciferase activity was measured in cell lysates. As shown in Figure 7 , Tax BLV activation of the wild-type LTR ranged from 54.2-to 558-fold. In comparison, Tax BLV activation of the pLTRmut1-luc construct ranged from 57.2-to 773-fold, indicating that mutation in the À95/À84 PU.1/Spi-B binding site did not reduce Tax BLV -mediated transactivation of the BLV LTR. These findings suggest that the PU.1/Spi-B site is not involved in the late stage of viral replication.
Discussion
In this report, we have physically and functionally characterized a PU.1/Spi-B binding site located in the U3 region of the BLV 5 0 LTR. We have demonstrated by in vitro binding experiments that this site centered on the GGAA core located at position À89/À92 in the viral promoter region is specifically bound by both PU.1 and Spi-B. Using transient transfection assays of B-lymphoid cell lines, we have shown that a point mutation abolishing PU.1/Spi-B binding caused a reproducible decrease in BLV promoter-driven gene expression, but did not affect the responsiveness of the BLV promoter to Tax BLV . Moreover, ectopically expressed PU.1 or Spi-B protein had a PU box-dependent stimulatory effect on the BLV promoter. The PU.1/Spi-B binding site identified here in the BLV LTR U3 region represents the first B-lymphoid-specific cis-regulatory element reported in the viral genome. PU.1 and SPI-B belong to the ETS family of transcription factors, which includes, among others, ETS-1, ETS-2, FLI-1, ELF, and ELK. All ETS family members share a conserved 85-amino-acid DNA-binding domain, termed the ETS domain (Karim et al., 1990) , that recognizes DNA sequences containing a GGA trinucleotide core (Wasylyk et al., 1993; MoreauGachelin, 1994) . Discrimination between potential ETSbinding sites appears to be governed both by the nucleotides flanking the G-G-A core sequence and by protein-protein interactions. The PU.1/Spi-1 gene was originally identified as a common integration site in Friend virus-induced erythroleukemia, resulting in the upregulation of PU.1/Spi-1 (Moreau-Gachelin et al., 1988 . During normal development, however, the tissue distribution of PU.1 is restricted to cells of the hematopoietic lineage, including B cells, megakaryocytes, granulocytes, mast cells, immature erythrocytes, and myeloid cells Ray et al., 1992; Hromas et al., 1993) . In contrast to PU.1, Spi-B expression is limited to B cells and immature T cells (Chen et al., 1995b; Su et al., 1996) . Spi-B was cloned based upon its homology to PU.1 (90% similar in the Ets domain), and has been shown to bind many of the same sites as PU.1 (although with different affinities) and transactivate some of the same genes as PU.1 (Ray et al., 1992; Su et al., 1996; Rao et al., 1999a, b) .
To date, no study has reported the existence of Blymphoid-specific cis-regulatory elements in the BLV genome. In this study, we have identified a binding site for the B-cell-specific ETS members PU.1 and Spi-B in the U3 region of the BLV LTR, suggesting that PU.1 and/or the highly related Spi-B protein could play a role in the B-lymphoid tropism of the virus (Dahl et al., 2002; Ray et al., 1992) . The essential role of PU.1 in regulating tissue-specific promoter activities has been demonstrated in B cells, macrophages, and monocytes (Dash et al., 1991) . Targeted disruption of the PU.1/Spi-1 gene in the mouse results in defective development of monocytes, granulocytes, and T-and B-cell progenitors (Scott et al., 1994) . In fact, many target genes for PU.1 have been identified in B cells (k 3 0 enhancer, Pongubala et al., 1992 Pongubala et al., , 1993 , l 2-4 enhancer, Eisenbeis et al., 1993 , heavy chain Em enhancer, Nelsen et al., 1993 , J chain promoter, Shin and Koshland 1993 , and Btk promoter, Himmelmann et al., 1996 , myeloid cells (CD11b, Chen et al., 1993; Pahl et al., 1993 , CD18, Rosmarin et al., 1995a , b, c-fes, Heydemann et al., 1996 , macrophage CSF (M-CSFR), Zhang et al., 1994 , granulocyte CSF (G-CSFR), Smith et al., 1996 , scavenger receptor, Horvai et al., 1995 , FCgRIIIA, Feinman et al., 1994 , FcgR1b, Perez et al., 1994 , interleukin-1b, Kominato et al., 1995 , myeloperoxidase, Ford et al., 1996 , and neutrophil elastase, Oelgeschlager et al., 1996) , mast cells (IL-4 gene enhancer, Henkel and Brown, 1994) , and erythroid cells (b-globin intervening sequence 2, Galson et al., 1993) . So far, several genes have been shown to be under the transcriptional control of PU.1 as well as Spi-B; these include the LMP/TP2 gene of the Epstein Barr virus (Laux et al., 1994) , the PU.1 gene itself (Chen et al., 1995a) , the Btk promoter (Muller et al., 1996) , the l 2-4 enhancer (Su et al., 1996) , the P2Y10 promoter (Rao et al., 1999a, b) , and the c-rel promoter (Hu et al., 2001) .
Our sequence analysis of the BLV LTR region first revealed the presence of two potential PU.1 binding sites. The distal site (1: nt -95/À84) matched exactly a large 12-bp Spi-1/PU.1 consensus sequence derived by Galson et al (1993) from several characterized PU boxes, whereas the proximal site (2: nt À88/À77) Figure 7 Effects of the PU box mutation mut1 on Tax-dependent BLV promoter-driven gene expression. Raji cells were transiently cotransfected with 500 ng of either pLTRwt-luc or pLTRmut1-luc and increasing amounts of the TAX BLV expression vector pSG-TAX BLV (0, 2, 8, 32, 128 , and 300 ng of plasmid DNA). To maintain the same amount of transfected DNA and to avoid squelching artefacts, the different amounts of pSG-TAX BLV cotransfected were complemented to 300 ng of DNA by using the pSG5 empty plasmid. Luciferase activity was measured in cell lysates 44 h after transfection. The results are presented as histograms indicating luciferase activities (arbitrary units) normalized to protein concentrations (top panel) or indicating the induction by Tax BLV (in fold) with respect to the activity of the same reporter construct in the absence of Tax BLV , which was assigned a value of 1 (bottom panel). Means and standard errors of the means are shown. A representative experiment of three independent transfections performed with at least two different DNA preparations is shown PU.1 and Spi-B regulate the BLV promoter A Dekoninck et al presented two mismatches (at positions À2 and +2 relative to the GGAA core) with respect to this consensus. A purine-rich motif (GGAA) is typically the minimal core sequence common to PU.1-responsive elements (Moreau-Gachelin, 1994) . However, several studies emphasize the importance of the sequences flanking the GGAA core for PU.1 binding by showing that the PU.1 ETS domain forms a series of specific contacts with both the GGAA core sequence and the nucleotides 3 0 and 5 0 to this core sequence Pio et al., 1996) . Our EMSA experiments using nuclear extracts or purified recombinant PU.1 protein demonstrate that only the distal PU.1 site of the BLV LTR binds PU.1 and Spi-B in vitro. These results are in agreement with the fact that the two nucleotides found at the 3 0 side of the distal GGAA core, namely G and T, are those occurring most frequently at these positions in functional PU.1 sites (Li et al., 1999) , and with the fact that the proximal site does not present the optimal flanking sequences to enable PU.1 binding.
NF-kB-like motifs have been previously reported in the À118/À70 region of the BLV 5 0 LTR (Brooks et al., 1995) . However, despite many attempts, we could not demonstrate the binding of NF-kB to this region by supershift or competition experiments using nuclear extracts and a BLV LTR probe. In agreement with the results reported by Brooks et al (1995) , we also observed the binding of purified NF-kB proteins to the À118/À70 probe. This binding could be because of a certain sequence homology between the À118/À70 probe and the NF-kB consensus sequence 5 0 -GGGRNNYYC-3 0 . Indeed, there are on the noncoding strand of the À118/ À70 region six sites presenting two to three mismatches with respect to this consensus. Based on our data, it seems most likely that the protection observed by Brooks et al (1995) in in vitro DNase I footprinting experiment using nuclear extracts is due, at least in part, to the binding of PU.1/Spi-B to the PU box identified in the present study.
Our functional results demonstrate a positive regulatory role of the PU.1/Spi-B binding site located in the U3 region of the BLV 5 0 LTR in Tax-independent BLV promoter-driven gene expression. Since Tax BLV expression is usually undetectable during viral latency in the infected B lymphocyte, the endogenous PU.1 and Spi-B proteins, in conjunction with CREB, ATF-1, ATF-2 (Adam et al., , 1996 , USF-1 and -2 (Calomme et al., 2002) , and IRFÀ1 and À2 (Kiermer et al., 1998) may provide the initial stimulation of BLV tanscription. This early BLV transcription would lead to the synthesis of small amounts of the Tax BLV transactivator, which could in turn amplify transcription of the viral genome. We have also studied the role of the PU.1/Spi-B site in the regulation of BLV-directed gene expression in presence of Tax BLV . Indeed, a direct interaction between PU.1 and the viral transactivator Tax HTLV has been previously reported in the context of the IL1B promoter (Tsukada et al., 1997) . However, our data showed that mutation of the BLV PU.1/Spi-B binding site did not affect the transactivation by Tax BLV . This PU.1/Spi-B site seems therefore not to be involved in the late stage of BLV replication.
Important PU.1 binding sites have been identified in the regulatory regions of several viruses. The enhancer element of the lymphotropic papovavirus, which contains a PU box required for its activity, contributes to the restricted tropism of the virus for primate Blymphocytes (Erselius et al., 1990) . The PU.1/Spi-1 binding site located in the EIAV LTR is a primary determinant of promoter activity in transfected monocyte cell lines, suggesting that it may be relevant to the macrophage tropism of the EIAV lentivirus Carvalho and Derse, 1993) . A PU.1/Spi-1 binding site has been identified by our laboratory in a transcriptional regulatory element, which is located in the pol gene of HIV-1 and is associated with a nucleasehypersensitive site. This intragenic-hypersensitive site is present only in a chronically HIV-1-infected cell line of monocytic origin and could thus represent a tissuespecific regulatory element (Van Lint et al., 1994) . Besides PU.1, other ETS family transcription factors are involved in promoter regulation of HTLV-I, a retrovirus closely related to BLV. The oncoprotein ETS-1 has been shown to activate HTLV-I transcription, and ELF-1 and ETS-1 have been demonstrated to bind to the HTLV-I LTR in a region named ERR-I (Bosselut et al., 1990; Gitlin et al., 1991; Clark et al., 1993) . Interestingly, the PU.1/Spi-B binding site we identified here in the BLV LTR and this ERR-I element in the HTLV-I LTR are located in similar regions, namely between the two TxREs that are the most proximal to the transcription initiation site. Of note, Tax HTLV -dependent enhancer of HTLV-I has been the subject of several studies (Clark et al., 1993; Gitlin et al., 1993; Seeler et al., 1993; Tanimura et al., 1993) . Interestingly, among these studies, Clark et al (1993) have reported that mutations in the purine-rich Ets-binding sites located in ERR-I element do not inhibit the response to Tax HTLV . This latter result parallels our data showing that mutation in the À95/À84 PU box of the BLV LTR does not impair activation of the viral promoter by Tax BLV .
Studies have established that BLV expression is influenced by intracellular pathways activated during B-lymphocyte blastogenesis (Jensen et al., 1992) . Phorbol 12-myristate 13-acetate (PMA) (Jensen et al., 1992) and lipopolysaccharide (LPS) (Lagarias and Radke, 1989) increase BLV expression in bovine BLV-infected PBMCs and in NBC-13 cells (a persistently BLVinfected B-lymphocyte cell line). Interestingly, these two lymphocyte activators have been shown to lead to phosphorylation of PU.1, a post-translational modification known to alter its capacity to modulate transcription (Carey et al., 1996; Mao et al., 1996; Lodie et al., 1997) . Experiments are underway to determine the potential role of the BLV LTR PU.1/Spi-B binding site in the inductibility of viral gene expression in response to activation of these two signaling pathways.
Moreover, we have ongoing studies to determine the chromatin organization of the BLV 5 0 LTR and more specifically the involvement of PU.1 in this organization. Indeed, previous studies have provided evidence that PU.1 may be involved in determining transcriptionally active chromatin structure Galson et al., 1993; Nikolajczyk et al., 1999) . Moreover, PU.1 has been shown to interact with chromatin-modifying enzymes: the histone acetyltransferase CREB binding protein (CBP) (Yamamoto et al., 1999) (which also interacts with Spi-B, Yamamoto et al., 2002) and the histone deacetylase HDAC1 (Kihara-Negishi et al., 2001) , further implicating PU.1 in chromatin remodeling.
Finally, further analysis of the functional role of the À95/À84 PU.1/Spi-B binding site will focus on characterizing the physiological relevance of this site in the context of the complete infectious BLV provirus. A BLV provirus mutated in this PU.1/Spi-B site will be constructed. This mutated provirus will be injected into sheep in order to test for infectivity and ability to induce pathogenesis. These in vivo experiments should provide new insight into the molecular mechanisms of BLV transcriptional activation.
Materials and methods

PBMCs isolation
Sheep PBMCs were isolated by Percoll gradient centrifugation as previously described (Calomme et al., 2002) .
Cell culture
The EBV-negative B-lymphoid cell lines DG75 and A20, the EBV-positive B-lymphoid cell line Raji, the monocytic cell line U937 and the T-lymphoid cell lines Jurkat and SupT1 were maintained in RPMI 1640-Glutamax I medium supplemented with 10% (DG75, Raji, U937, Jurkat and SupT1) or 5% (A20) fetal bovine serum. The EBV-positive B-cell line Daudi was grown in RPMI 1640-Glutamax I medium supplemented with 10% fetal bovine serum, 10 mm HEPES buffer, 1 mm sodium pyruvate. The adherent cell lines RAW (a murine macrophagic cell line), Cos-7 (a simian fibroblastic cell line), HeLa (a human epithelial cell line), and NIH3T3 (a murine fibroblastic cell line) were cultured in Dubelcco's modified Eagle's-Glutamax I medium containing 5% fetal bovine serum (RAW, Cos-7 and HeLa) or 10% calf serum (NIH3T3). For the RAW cells, the medium was also supplemented with 1% sodium pyruvate and 10 mm HEPES buffer. All media also contained 50 U of penicillin/ml and 50 mg of streptomycin/ml. All media, sera (Myoclone Superplus), and supplements were from Invitrogen. All cells were grown at 371C in a 5% CO 2 atmosphere.
Plasmid constructs
The pLTRwt-luc was previously described (Calomme et al., 2002) and contains the firefly luciferase gene under the control of the complete 5 0 LTR of the 344 BLV provirus (Willems et al., 1993) . This vector was used as a substrate for mutagenesis by the QuickChange Site-Directed Mutagenesis method (Stratagene). Different mutations were generated with the following pairs of mutagenic oligonucleotide primers (mutations are highlighted in bold and the two potential PU boxes are underlined on the coding strand primer): CV441/ 442(À118/À70-mut1): 5 0 -GGCTAGAATCCCCGTACCTCC-CCAACTTGGCCTTTCCCGAAAAATCCAC-3 0 , CV 443/444 (À118/À70-mut2): 5 0 -GGCTAGAATCCCCGTACCTCCC-CAACTTCCCCTTTGGCGAAAAATCCAC-3 0 , CV 376/377 (À118/À70-mut1+2): 5 0 -GGCTAGAATCCCCGTACCTCC-CCAACTTGGCCTTTGGCGAAAAATCCAC-3 0 . Mutated constructs were fully resequenced after identification by cycle sequencing using the Thermosequenase DNA sequencing kit (Amersham Biosciences). The three mutated plasmids were designated pLTRmut1-luc, pLTRmut2-luc, and pLTRmut1+2-luc, respectively.
The PU.1 expression vector pJ6-PU.1 was previously described . The Spi-B expression vectors DEB-Spi-B and pcDNA3-Spi-B were gifts from Dr Franc¸oise Moreau-Gachelin (Institut Curie, Paris, France) and from Dr Simon Celeste (Howard Hughes Medical Institute, Philadelphia, PA, USA), respectively. The eukaryotic expression vector pSG-TAX BLV was a gift from Drs Luc Willems and Richard Kettmann (Faculty of Agronomy, Gembloux, Belgium).
Transient transfection and luciferase reporter assays
Raji and A20 cells were transfected by using the DEAEdextran procedure as previously described (Van Lint et al., 1994; Calomme et al., 2002) . At 44 h post-transfection, cells were lysed and assayed for luciferase activity (Promega). Luciferase activities derived from BLV LTRs were normalized with respect to protein concentrations using the DetergentCompatible Protein Assay (Bio-Rad).
DG75 and Daudi cells were transfected by electroporation at 960 mF and 250 V, as previously described (Calomme et al., 2002) . All transfection mixtures contained the pRL-TK, in which a cDNA encoding Renilla luciferase is under the control of the herpes simplex virus thymidine kinase promoter region, and is used as an internal control for transfection efficiency. At 48 h post-transfection, luciferase activities (firefly and Renilla) were measured in cell lysates and firefly luciferase activities derived from the BLV promoters were normalized with respect to the Renilla luciferase activities by using the dual luciferase reporter assay system (Promega).
FuGENE transfection of HeLa and Cos-7 cells was performed as previously described (Calomme et al., 2002) . At 44 h post-transfection, cells were lysed and assayed for luciferase activity (Promega). Luciferase activities derived from BLV LTRs were normalized with respect to protein concentrations using the Detergent-Compatible Protein Assay (Bio-Rad).
NIH3T3 cells were transfected by the calcium phosphate precipitate method (Profection Kit, Promega). At 24 h prior transfection, cells were seeded at a density of 2 Â 10 5 cells per well in six-well plates. 6 mg of plasmid DNA was mixed with CaCl 2 and phosphate buffer (as described by the manufacturer), incubated at room temperature for 30 min to allow DNA precipitation and added to the cells. After a 18 h incubation in the presence of the transfection complexes, the medium was changed and the cells were grown at 371C for an additional 26 h period. Cells were then lysed and assayed for luciferase activity (Promega) as described for Daudi cells.
Expression and purification of GST fusion proteins
The glutathione S-transferase (GST)-p50 and (GST)-p65 fusion vectors were obtained from Dr Vincent Bours (Center for Molecular and Cellular Therapy, Universite´de Lie`ge, Belgium) and the fusion proteins were expressed as previously described (Kiernan et al., 1999) .
Electrophoretic mobility shift assays (EMSAs)
Nuclear extracts were prepared by a rapid method described by Osborn et al (1989) . All buffers contained the protease inhibitors antipain (10 mg/ml), aprotinin (2 mg/ml), chymostatin (10 mg/ml), leupeptin (1 mg/ml), and pepstatin (1 mg/ml). Protein concentrations were determined by the method of Bradford (1976) . The DNA sequences of the oligonucleotides used for this study are listed in Figures 1a and 4a or in the figure legends. The gel shift reaction and electrophoresis conditions have been described previously (Calomme et al., 2002) . For supershift assays, 2-4 mg of a specific antibody was added to the reaction mixture and incubated for 30 min on ice before the addition of the radiolabeled probe. The following antibodies were used: specific monoclonal anti-serum to c-Rel (sc-6955X); specific polyclonal antisera to RelB (sc-226X), p65 (sc-109X), c/EBPb (sc-150X), and ICSBP (sc-6058X) (Santa Cruz Biochemicals, Santa Cruz, CA, USA); specific polyclonal antisera to p52 (06-413), p50 (06-886) (Upstate Biotechnology Inc); anti-PU.1 antibody (Quang et al., 1995) ; anti-GABP antibody (a gift from Dr Kitajima, Medical Research Institute, Tokyo, Japan); anti-Pax5 antibody (a gift from Dr Busslinger, Research Institute of Molecular Pathology, Vienna, Austria); anti-Spi-B antibody (a gift from Dr Moreau-Gachelin, Institut Curie, Paris, France).
For analysis of PU.1 binding, whole-cell extracts of Spodoptera frugiperda SF9 cells infected with a recombinant Ac-NPV-PU.1 baculovirus were used as a source for PU.1 protein and extracts from uninfected insect cells were used as a control. Conditions for EMSAs were as previously described (Bosselut et al., 1990) .
For analysis of p50 and p65 binding, 100 ng of GST-p50 or GST-p65 was used as a source for p50 and p65 proteins. EMSAs were performed as described above (0.4 mg of poly(dIdC) was used).
